Skip to main content
Erschienen in: Current Allergy and Asthma Reports 3/2011

01.06.2011 | Invited Commentary

What to Do With Refractory Urticaria Patients

verfasst von: Allen P. Kaplan

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Excerpt

A urticaria patient said to be refractory to treatment ordinarily implies inadequate responsiveness to antihistamines. Thus, it is necessary to define at what point antihistamine therapy has failed. Although virtually any first-generation or second-generation antihistamine has efficacy for treatment of urticaria, few studies have compared one agent to the others, and dose-escalation studies are much in need. For the past 40 years, when first-generation antihistamines were all we had, I advocated use of hydroxyzine (Atarax; Pfizer, New York, NY) or diphenhydramine (Benadryl; McNeil-PPC, Fort Washington, PA) at doses up to 50 mg four times daily before assuming a patient to be refractory [1]. These agents ware relatively short-acting and were meant to be used in divided doses four times daily when necessary. For patients with physically induced hives such as cold urticaria or cholinergic urticaria, one could readily titrate the antihistamine dose and determine that 3 or 4 doses/d are frequently required where 1 or 2 doses do not provide adequate symptom control. Once the relatively nonsedating, second-generation, long-acting drugs were available, they were commended once daily for urticaria, as was recommended for allergic rhinitis. This turned out to be effective only in the mildest of cases of urticaria. Recently, when loratadine was tested for efficacy in the treatment of cold urticaria, it was clear that 4 > 3 > 2 > 1 tablets/d (ie, more is better, and side effects are minimal). In spite of the evidence of sedation with first-generation antihistamines [25], when they are used in high doses, sedation rapidly wears off, and they can still be recommended in countries in which second-generation agents are not available [6, 7]. There are, in fact, very few studies of sedation with use of such agents for more than a week in patients with chronic urticaria rather than in healthy volunteers. Nevertheless, for most purposes, this becomes a moot point, particularly when cost ceases to be an issue. Thus, over-the-counter generic cetirizine can be obtained inexpensively, and 6 tablets/d is roughly equivalent to hydroxyzine, 200 mg/d. …
Literatur
1.
Zurück zum Zitat Kaplan A. What the first 10,000 patients with chronic urticaria have taught me: a personal journey. J Allergy Clin Immunol. 2009;123:713–7.PubMedCrossRef Kaplan A. What the first 10,000 patients with chronic urticaria have taught me: a personal journey. J Allergy Clin Immunol. 2009;123:713–7.PubMedCrossRef
2.
Zurück zum Zitat Weiler J, Bloomfield J, Woodworth G, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Int Med. 2000;132:354–63.PubMed Weiler J, Bloomfield J, Woodworth G, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Int Med. 2000;132:354–63.PubMed
3.
Zurück zum Zitat Verster J, Volkerts E, van Oosterwijck A, et al. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J Allergy Clin Immunol. 2003;111:623–7.PubMedCrossRef Verster J, Volkerts E, van Oosterwijck A, et al. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J Allergy Clin Immunol. 2003;111:623–7.PubMedCrossRef
4.
Zurück zum Zitat Ramaekers J, O'Hanlon J. Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing. European J Clin Pharm. 1994;47:261–6.CrossRef Ramaekers J, O'Hanlon J. Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing. European J Clin Pharm. 1994;47:261–6.CrossRef
5.
Zurück zum Zitat Church M, Maurer M, Simons F, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65:459–66.PubMedCrossRef Church M, Maurer M, Simons F, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65:459–66.PubMedCrossRef
6.
Zurück zum Zitat Bender B, Berning S, Dudden R, et al. Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. J Allergy Clin Immunol. 2003;111:770–6.PubMedCrossRef Bender B, Berning S, Dudden R, et al. Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. J Allergy Clin Immunol. 2003;111:770–6.PubMedCrossRef
8.
Zurück zum Zitat Boyce J. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006;117:1415–8.PubMedCrossRef Boyce J. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006;117:1415–8.PubMedCrossRef
9.
Zurück zum Zitat Houser D, Arbesman C, Ito K, et al. Cold urticaria. Immunologic studies. Am J Med. 1970;49:23–33.PubMedCrossRef Houser D, Arbesman C, Ito K, et al. Cold urticaria. Immunologic studies. Am J Med. 1970;49:23–33.PubMedCrossRef
10.
Zurück zum Zitat Kaplan A, Garofalo J, Sigler R, et al. Idiopathic cold urticaria: in vitro demonstration of histamine release upon challenge of skin biopsies. N Engl J Med. 1981;305:1074–7.PubMedCrossRef Kaplan A, Garofalo J, Sigler R, et al. Idiopathic cold urticaria: in vitro demonstration of histamine release upon challenge of skin biopsies. N Engl J Med. 1981;305:1074–7.PubMedCrossRef
11.
13.
Zurück zum Zitat Guzelbey O, Ardelean E, Magerl M, et al. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63:1563–5.PubMedCrossRef Guzelbey O, Ardelean E, Magerl M, et al. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63:1563–5.PubMedCrossRef
14.
Zurück zum Zitat Waibel K, Reese D, Hamilton R, et al. Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol. 2009;125:490–1.CrossRef Waibel K, Reese D, Hamilton R, et al. Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol. 2009;125:490–1.CrossRef
15.
Zurück zum Zitat Estes S, Yung C. Delayed pressure urticaria: an investigation of some parameters of lesion induction. J Am Acad Dermatol. 1981;5:25–31.PubMedCrossRef Estes S, Yung C. Delayed pressure urticaria: an investigation of some parameters of lesion induction. J Am Acad Dermatol. 1981;5:25–31.PubMedCrossRef
16.
Zurück zum Zitat Barlow R, Ross E, MacDonald D, et al. Adhesion molecule expression and the inflammatory cell infiltrate in delayed pressure urticaria. Br J Dermatol. 1994;131:341–7.PubMedCrossRef Barlow R, Ross E, MacDonald D, et al. Adhesion molecule expression and the inflammatory cell infiltrate in delayed pressure urticaria. Br J Dermatol. 1994;131:341–7.PubMedCrossRef
17.
Zurück zum Zitat Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009;64:1427–43.PubMedCrossRef Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009;64:1427–43.PubMedCrossRef
18.
Zurück zum Zitat Hide M, Francis D, Grattan C, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328:1599–604.PubMedCrossRef Hide M, Francis D, Grattan C, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328:1599–604.PubMedCrossRef
19.
Zurück zum Zitat Kikuchi Y, Kaplan A. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol. 2001;107:1056–62.PubMedCrossRef Kikuchi Y, Kaplan A. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol. 2001;107:1056–62.PubMedCrossRef
20.
Zurück zum Zitat Leznoff A, Sussman G. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol. 1989;84:66–71.PubMedCrossRef Leznoff A, Sussman G. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol. 1989;84:66–71.PubMedCrossRef
21.
Zurück zum Zitat Kikuchi Y, Fann T, Kaplan A. Antithyroid antibodies in chronic urticaria and angioedema. J Allergy Clin Immunol. 2003;112:218.PubMedCrossRef Kikuchi Y, Fann T, Kaplan A. Antithyroid antibodies in chronic urticaria and angioedema. J Allergy Clin Immunol. 2003;112:218.PubMedCrossRef
22.
Zurück zum Zitat Staevska M, Popov T, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125:676–82.PubMedCrossRef Staevska M, Popov T, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125:676–82.PubMedCrossRef
23.
Zurück zum Zitat Grattan C, O'Donnell B, Francis D, et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol. 2000;143:365–72.PubMedCrossRef Grattan C, O'Donnell B, Francis D, et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol. 2000;143:365–72.PubMedCrossRef
24.
Zurück zum Zitat Kessel A, Toubi E. Cyclosporine A in severe chronic urticaria: the option for long-term therapy. Allergy. 2010;65:1478–82.PubMedCrossRef Kessel A, Toubi E. Cyclosporine A in severe chronic urticaria: the option for long-term therapy. Allergy. 2010;65:1478–82.PubMedCrossRef
25.
Zurück zum Zitat Kaplan A, Joseph K, Maykut R, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122:569–73.PubMedCrossRef Kaplan A, Joseph K, Maykut R, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122:569–73.PubMedCrossRef
26.
Zurück zum Zitat Spector S, Tan R. Effect of omalizumab on patients with chronic urticaria. Annals Allergy Asthma Immunol. 2007;99:190–3.CrossRef Spector S, Tan R. Effect of omalizumab on patients with chronic urticaria. Annals Allergy Asthma Immunol. 2007;99:190–3.CrossRef
27.
Zurück zum Zitat Dreyfus D. Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema. Annals Allergy Asthma Immunol. 2008;100:624–5.CrossRef Dreyfus D. Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema. Annals Allergy Asthma Immunol. 2008;100:624–5.CrossRef
28.
Zurück zum Zitat Ferrer M, Gamboa P, Sanz M, et al. Omalizumab is effective in non-autoimmune urticaria. J Allergy Clin Immunol 2011 (in press). Ferrer M, Gamboa P, Sanz M, et al. Omalizumab is effective in non-autoimmune urticaria. J Allergy Clin Immunol 2011 (in press).
Metadaten
Titel
What to Do With Refractory Urticaria Patients
verfasst von
Allen P. Kaplan
Publikationsdatum
01.06.2011
Verlag
Current Science Inc.
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 3/2011
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-011-0187-6

Weitere Artikel der Ausgabe 3/2011

Current Allergy and Asthma Reports 3/2011 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.